SKF-81,297

SKF-81,297 is a synthetic drug of the benzazepine chemical class that acts as a selective D1/D5 receptor full agonist, and produces a characteristic stimulant effect in animals, distinct from that of other known dopaminergic stimulants.

Pharmacology

SKF-81,297 was developed by the pharmaceutical company Smith, Kline & French in the 1980s, as part of their research into drugs for treating Parkinson's disease. It is most commonly used in scientific research into the dopamine system, particularly the role of the D1 receptor subtype in the effects of drugs of abuse.

SKF-81,297 acts as a full agonist at the D1-D5 dopamine receptors, with the highest affinity for the D1 and D5 subtypes. It has little affinity for the D2-D4 subtypes. The drug has a high bioavailability and a fast onset of action, although its duration of action is relatively short.

Effects

The effects of SKF-81,297 in animals include locomotor activation, stereotypy, and self-administration, all of which are characteristic of dopaminergic stimulants. However, the drug also produces effects that are not typically seen with other stimulants, such as a reduction in food intake and a potentiation of the effects of other drugs of abuse.

Research

Research into SKF-81,297 has provided valuable insights into the role of the D1 receptor in the effects of drugs of abuse. For example, studies have shown that the drug can potentiate the effects of cocaine and amphetamine, suggesting that D1 receptor activation may be involved in the reinforcing effects of these drugs. Other research has focused on the potential therapeutic uses of D1 receptor agonists, such as in the treatment of Parkinson's disease and drug addiction.

See also

• Dopamine receptor D1
• Dopamine receptor D5
• Benzazepine
• Stimulant
• SKF

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

• 
  SKF-81,297